Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Prospective, Randomised, Open Label Study to Compare the Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg PR in Subjects With Active Acromegaly

NCT02493517 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT02493517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02493517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Prospective, Randomised, Open Label Study to Compare the Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg PR in Subjects With Active Acromegaly
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2014
Completion date
February 16, 2017
Enrollment
128 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly